YMTHE, Volume 31

Supplemental Information

ROCK inhibition enhanced hepatocyte liver

engraftment by retaining membrane CD59

and attenuating complement activation

Haoxin Ma, Chao Wang, Shulong Liang, Xinlu Yu, Yuan Yuan, Zhuanman Lv, Jiqianzhu Zhang, Caixia Jin, Jiangbo Zhu, Chao Wang, Pingxin Sun, and Wenlin Li



Figure S1. Representative bioluminescence images of mice transduced with replication-

incompetent AAV2/8-CAG-EGFP-T2A-lucifrase.



Figure S2. The daily time course of flux values of transplanted hepatocytes with ripasudil treatment for 7 days. Data are shown as the means ± SEMs (n=3). n.s, no significance. **

P<0.01.



Figure S3. RKI-1447, another ROCK inhibitor with a different chemical scaffold from that

of ripasudil, enhances hepatocyte liver engraftment. RKI-1447 (ROCK inhibitor, 80 mg/kg) was administered once intraperitoneally soon after cell transplantation. The mice were analyzed at 5 days, 2 weeks, and 7 weeks after transplantation. Data are shown as

the means ± SEMs (n=4). *p < 0.05. ** P<0.01.



Figure S4. The viability of hepatocytes isolated with perfusion and digestion buffer supplemented with 4 μ M ripasudil or RKI-1447. Arrow indicated the cells stained with trypan blue. The scale bars represent 50 μ M. Data are expressed as the means ± SEMs

of four independent hepatocyte isolation experiments.



Figure S5. Ripasudil inhibited hepatocyte endocytosis and retained cell membrane Ecadherin. (A) Endocytosis of isolated hepatocytes was demonstrated by pHrodo Red dextran staining. (B) The expression of E-cadherin in isolated hepatocytes was analyzed by immunostaining after treatment with ripasudil or vehicle control. (C) The expression of E-cadherin in the liver and isolated hepatocytes was analyzed by western blotting. The scale bars represent 50 µM in Panel A and 100 µM in Panel B.





RNA-seq data for freshly isolated hepatocytes.



Figure S7. Ripasudil maintains hepatocyte membrane protein homeostasis dependent on protein neosynthesis. The expression of E-cadherin and CD59a in isolated hepatocytes was analyzed by western blotting after treatment with ripasudil, puromycin and

actinomycin D.



Figure S8. The liver engraftment of hepatocytes expressing control shRNA was analyzed

by bioluminescence imaging 3 days after cell transplantation. Data are shown as the

means \pm SEMs of three independent experiments. *p < 0.05.



Figure S9. Overexpression of CD59a enhanced hepatocyte liver engraftment. (A) The expression of CD59a in isolated hepatocytes transduced with pAAV-TBG-Cd59a-WPRE or pAAV-TBG-Cre-WPRE was analyzed by immunostaining. (B) CD59a expression by hepatocytes transduced with pAAV-TBG-Cd59a-WPRE or pAAV-TBG-Cre-WPRE was analyzed by western blot. (C and D) Fluorescence images and flow cytometry analysis of

1:1 pooled mTmG hepatocytes transduced with pAAV-TBG-Cd59a-WPRE (red hepatocytes) and pAAV-TBG-Cre-WPRE (green hepatocytes). (E) Fluorescence images of liver sections transplanted with pooled mTmG hepatocytes transduced with pAAV-TBG-Cd59a-WPRE (red hepatocytes) and pAAV-TBG-Cre-WPRE (green hepatocytes). The mice were analyzed at 7 days after transplantation. (F) Quantitative analysis of Panel E. The scale bars represent 50 μM. Data are shown as the means ± SEMs of three independent experiments. **p < 0.01.



Figure S10. Ripasudil treatment has no impact on liver function in $Fah^{-/-}$ mice. Serum analysis of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in $Fah^{-/-}$ $h^{-/-}$ mice at 4 weeks after mock transplantation under treatment with ripasudil or vehicle

control.



Figure S11. The engraftment of hepatocytes was analyzed by bioluminescence imaging in mice preconditioned with hepatic irradiation and treated with ripasudil. The mice were analyzed at 3 days and 7 days after transplantation. Data are shown as the means ±

SEMs (n=4). *p < 0.05. ** P<0.01.

Table S1. shRNA sequences.

shRNA	Hairpin sequence (5'-3')
CD59a shRNA1	CACCG <u>CGGTGGTTTCTTCATGCAATA</u> CTCGAGTATTGC
	ATGAAGAAACCACCGTTTTT
CD59a shRNA2	CACCG <u>TTGTCATGGTGAGATCATTAT</u> CTCGAGATAATGA
	TCTCACCATGACAATTTTT
CD59a shRNA3	CACCG <u>CCAGGATTCCTGTCTCTAT</u> TTCAAGAGAATAGAG
	ACAGGAATCCTGGTTTTT
Scramble shRNA	CACCG <u>TTCTCCGAACGTGTCACGT</u> TTCAAGAGAACGTG
	ACACGTTCGGAGAATTTTT

The target sequences are underlined.

Table S2. Antibodies used in immunocytochemistry, immunohistochemistry and western

blot.

Antibodies	Source	Application	Dilution
Anti-E-Cadherin, rat	Santa Cruz, sc-		200
monoclonal antibody	59778	Immunocytocnemistry	
Anti-DPP4, goat	R&D, AF954	immunohistochemistry	0.5 µg/ml
polyclonal antibody			
Anti-F4/80, rat	Santa Cruz, sc-	Immunocytochemistry/ 200 immunohistochemistry	000
monoclonal antibody	52664		200
Anti-CD59a, rabbit	Sino Biological,	immunocytochemistry	200
monoclonal antibody	50724-R108		
Anti-C5b-9, mouse	Santa Cruz, sc-	Immunocytochemistry/ immunohistochemistry	200
monoclonal antibody	66190		
Anti-E-Cadherin, rabbit	Cell Signaling	western blot	1000
monoclonal antibody	Technology, 3195S		
Anti-CD59, rat	Santa Cruz, sc-	western blot	500
monoclonal antibody	59095		
Anti-GAPDH, mouse	Proteintech, 60004-	western blot	20000
monoclonal antibody	1-lg		
Anti-β-Actin, HRP-		western blot	2000
conjugated monoclonal	Proteintech, HRP-		
antibody	60008		

Table S3. PCR primers used in qRT–PCR experiments.

Genes	Forward (5'-3')	Reverse (5'-3')
Gapdh	TGGCAAAGTGGAGATTGTTGCC	AAGATGGTGATGGGCTTCCCG
CD59a	TCAATCTGGCTGGGGATGTG	TGAGGCTAACAGCTGTGGAA